ANANDA Scientific and the David Geffen School of Medicine at UCLA have announced the launch of a clinical trial to evaluate Nantheia™ ATL5 for smoking cessation

GREENWOOD VILLAGE, Colorado & LOS ANGELES–(BUSINESS WIRE)–ANANDA Scientific Inc., a research-focused biopharmaceutical company, and the Semel Institute for Neuroscience at the Geffen School of Medicine at UCLA, announced today the start of a clinical trial to evaluate the Nantheia™ ATL5 , an experimental drug that combines cannabidiol (CBD) with proprietary delivery technology by ANANDA , to evaluate the effectiveness of cannabidiol in smoking cessation. (ClinicalTrials.gov ID: NCT06218056)

This trial is being conducted by the principal investigator, Dr. Edythe London , Professor Emeritus of Psychiatry and Biobehavioral Sciences, and Molecular and Medicinal Pharmacology at the Semel Institute of the Geffen School of Medicine at UCLA. Funding for this trial is provided by a grant from the Center for Medicinal Cannabis Research.

«We are delighted to have begun this clinical trial focusing on the Nantheia™ ATL5 »in partnership with Ananda,« said Dr. London. »Tobacco use remains a major health problem worldwide, and we are committed to developing new, evidence-based approaches to reduce tobacco use and nicotine addiction.".

« ANANDA is delighted to be collaborating once again with Dr. London and the Geffen School of Medicine on this pivotal trial of our investigational drug, »the Nantheia™ ATL5" emphasized Sohail R. Zaidi CEO, by ANANDA. «This clinical trial is a major part of our clinical development efforts, which are focused on developing non-addictive treatments for significant health issues.».

During this randomized, double-blind, placebo-controlled study, participants will be administered the Nantheia ^™ ATL5 (800 mg of CBD) or a placebo every day for 8 weeks. The primary outcome measure will be the reduction in cigarette consumption compared to baseline. Secondary endpoints will assess the impact of nicotine withdrawal and its effects on general anxiety and mood.

ABOUT NANTHEIA™ ATL5

The Nantheia™ ATL5 is an experimental drug that combines cannabidiol and technology exclusive right to administer’ANANDA, Liquid Structure™. Preclinical studies and early clinical trials demonstrate that the proprietary delivery technology for’ANANDA Liquid Structure™ (under license from Lyotropic Delivery Systems (LDS) Ltd. in Jerusalem, Israel) improves the efficacy, uniform absorption, and stability of cannabidiol. The Nantheia™ ATL5 is an oral medication containing 100 mg of cannabidiol per soft gelatin capsule.

ABOUT ANANDA SCIENTIFIC

ANANDA Scientific is a leading research-based biopharmaceutical company specializing in the development of life-changing medications that transform neuropsychiatric health. It is currently conducting cutting-edge clinical trials to evaluate the Nantheia™ for therapeutic indications such as PTSD, pain, anxiety, opioid use disorder, and smoking cessation. Thanks to its proprietary delivery technology, the cannabinoids and plant-derived compounds are highly bioavailable, water-soluble, and stable over time. ANANDA Scientific Its mission is to manufacture effective, high-quality pharmaceutical products that improve patients' lives.

This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current assumptions and expectations, which are subject to change over time.

The text of the press release resulting from a translation must in no way be considered as official. The only authentic version of the press release is the one in its original language. The translation must always be compared with the source text, which will be the legal precedent.

Contact

ANANDA Scientific – Media Relations

Chris Moore | 813-326-4265

[email protected]